No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.
Purpose: Rosuvastatin disposition is modulated by the expression and activity of several membrane transporters including BCRP (ABCG2). The objective of our study was to investigate the effects of pantoprazole, a previously proposed BCRP inhibitor, on the disposition of rosuvastatin. Methods: The imp...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 72; no. 8; pp. 925 - 932 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | clinical trial equations & formulas research tables/charts Journal Article |
| Publicado: |
Springer Nature
Aug2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=116775248&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 116775248 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00316970 NP9 jtl: European Journal of Clinical Pharmacology issn: 00316970 maglogo: N pubinfo: dt: Aug2016 vid: 72 iid: 8 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 116775248 116775248 116775248 10.1007/s00228-016-2065-6 116775248 ppf: 925 ppct: 7 formats: fmt: @attributes: type: P tig: atl: No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects. aug: au: Huguet, J. Lu, J. Gaudette, F. Chiasson, J.-L. Hamet, P. Michaud, V. Turgeon, J. affil: CRCHUM, Centre de recherche du Centre hospitalier de l'Université de de Montréal, 900 Saint-Denis Street Montréal H2X 0A9 Canada sug: subj: Rosuvastatin Pharmacokinetics Pantoprazole Sodium Contraindications Drug Interactions Membrane Transport Proteins Antagonists and Inhibitors Human Descriptive Statistics Confidence Intervals Odds Ratio Rosuvastatin Blood Metabolic Clearance Rate Evaluation Clinical Trials ab: Purpose: Rosuvastatin disposition is modulated by the expression and activity of several membrane transporters including BCRP (ABCG2). The objective of our study was to investigate the effects of pantoprazole, a previously proposed BCRP inhibitor, on the disposition of rosuvastatin. Methods: The impact of pantoprazole (40 mg ID for 2 days) on rosuvastatin pharmacokinetics was evaluated in healthy volunteers ( n = 16) who received a single oral dose of rosuvastatin (10 mg) either alone or with pantoprazole. Rosuvastatin, N-desmethylrosuvastatin, and rosuvastatin lactone levels were quantified in plasma while rosuvastatin and N-desmethylrosuvastatin excretion were measured in urine. Results: Ratios and 90 % standard confidence interval of geometric means for C (1.03 [0.91-1.16]), AUC (1.03 [0.89-1.19]) and renal clearance (0.96 [0.85-1.09]) were all within the pre-specified range of 0.8-1.25, indicating a lack of drug-drug interaction between pantoprazole and rosuvastatin. Conclusions: Concomitant administration of pantoprazole with rosuvastatin did not affect rosuvastatin plasma concentrations. The use of pantoprazole as a BCRP inhibitor should be revisited when characterizing BCRP-mediated transport in humans. pubtype: Academic Journal doctype: clinical trial equations & formulas research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|